Regions – Page 44 – pharmaceutical daily

December 7, 2021 Off

Medicago and GSK receive good news for its plant-based COVID-19 vaccine candidate

Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) have received positive efficacy and safety results from the global Phase 3 placebo-controlled efficacy study of Medicago’s plant-based COVID-19 vaccine candidate in combination with GSK’s pandemic adjuvant, conducted in over 24,000 subjects, adults 18 years and above, across six countries.

December 7, 2021 Off

Pure Tech kicks off study for its neuro conditions treatment candidate

By Dino Mustafić

PureTech Health has kicked off a clinical study of LYT-300 (oral allopregnanolone), its wholly-owned therapeutic candidate for the potential treatment of neurological and neuropsychological conditions, including depression, anxiety, sleep disorders, fragile X tremor-associated syndrome, essential tremor and epileptic disorders, among others. LYT-300 is the third clinical-stage, wholly-owned candidate from PureTech’s pipeline.

December 7, 2021 Off

Bavarian Nordic A/S issues 6,373,680 New Ordinary Shares

By GlobeNewswire

Bavarian Nordic A/S (“Bavarian Nordic” or the “Company”) announced its intention to raise new capital through an accelerated bookbuilding process.…

October 12, 2021 Off

Hikma launches Micafungin for Injection

By Dino Mustafić

Hikma Pharmaceuticals has announced it launched Micafungin for Injection through its US affiliate, Hikma Pharmaceuticals USA Inc. The company has launched 50mg and 100mg doses.

October 11, 2021 Off

Sandoz completes acquisition of GSK’s cephalosporin business

By Dino Mustafić

Sandoz, a Novartis division, has acquired rights to three established brands (Zinnat, Zinacef and Fortum) in more than 100 markets,…

October 5, 2021 Off

Merck to seek emergency use authorization for Molnupiravir, oral antiviral medicine for COVID-19

By Dino Mustafić

The drug maker Merck said it plans to seek emergency use authorization in the U.S. as soon as possible and to submit applications to regulatory agencies worldwide for Molnupiravir, which could be the first oral antiviral medicine for COVID-19.

September 30, 2021 Off

Novartis data show rapid and effective disease activity control with remibrutinib in patients with chronic spontaneous urticaria

By Dino Mustafić

Novartis today announced positive Phase IIb data showing remibrutinib (LOU064), a potentially best-in-class oral BTK inhibitor, demonstrated rapid and effective disease control in patients with inadequately controlled chronic spontaneous urticaria (CSU).

September 30, 2021 Off

LEO Pharma shared new Adtralza results

By Dino Mustafić

LEO Pharma shared results showing that after two years of continuous treatment with Adtralza, adult patients with moderate-to-severe atopic dermatitis maintained improvements in signs and symptoms, itch severity and sleep interference

September 29, 2021 Off

Novartis data show achieving complete control of chronic spontaneous urticaria (CSU) improves overall quality of life

By Dino Mustafić

Novartis’ dana from new analysis from a Phase IIb study has showed the importance of achieving complete control of chronic spontaneous urticaria (CSU) symptoms in improving overall health-related quality of life (HRQoL) for patients, as complete control of symptoms brings enormous benefit to people with CSU and is associated with improvements in key HRQoL measures such as overall quality of life, sleep interference, activity interference and work impairment.

September 20, 2021 Off

Cellbox Solutions kicks off subsidiary in the USA

By Dino Mustafić

Cellbox Solutions GmbH, developer of the patented Cellbox technology, has founded their U.S. company and is now selling products directly to the U.S./North American market.